Get the Stockscreener App
1.695
2.31%
-0.035
Outlook Therapeutics Inc stock is traded at $1.695, with a volume of 282.88K.
It is down -2.31% in the last 24 hours and down -26.52% over the past month.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
See More
Previous Close:
$1.73
Open:
$1.74
24h Volume:
282.88K
Relative Volume:
0.14
Market Cap:
$56.28M
Revenue:
-
Net Income/Loss:
$-51.50M
P/E Ratio:
-0.4238
EPS:
-4
Net Cash Flow:
$-47.10M
1W Performance:
-17.96%
1M Performance:
-26.52%
6M Performance:
-75.89%
1Y Performance:
-79.92%
1-Day Range:
$1.68
$1.78
1-Week Range:
$1.65
$1.99
52-Week Range:
$0.87
$12.85
Outlook Therapeutics Inc Stock (OTLK) Company Profile
Name
Outlook Therapeutics Inc
Sector
Industry
Phone
(609) 619-3990
Address
111 S. WOOD AVENUE, ISELIN, NJ
Compare OTLK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OTLK
Outlook Therapeutics Inc
|
1.6967 | 56.28M | 0 | -51.50M | -47.10M | -4.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.33 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.93 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.50 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Outlook Therapeutics Inc Stock (OTLK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-02-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Mar-27-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-15-24 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-25-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-27-23 | Upgrade | CapitalOne | Equal Weight → Overweight |
| Aug-31-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Aug-31-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-30-23 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-30-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Aug-30-23 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Aug-30-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-13-23 | Initiated | CapitalOne | Overweight |
| Apr-03-23 | Initiated | Guggenheim | Buy |
| Feb-06-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-31-22 | Initiated | BTIG Research | Buy |
| Sep-13-22 | Initiated | Chardan Capital Markets | Buy |
| Sep-11-19 | Initiated | Ladenburg Thalmann | Buy |
| May-16-19 | Initiated | Oppenheimer | Outperform |
| Apr-22-19 | Initiated | Ascendiant Capital Markets | Buy |
View All
Outlook Therapeutics Inc Stock (OTLK) Latest News
Outlook Therapeutics (OTLK) Expected to Announce Earnings on Wednesday - MarketBeat
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Holdings of Outlook Therapeutics Inc (OTLK) are aligned with the stars - SETE News
Outlook Therapeutics Inc (OTLK) produces promising results - US Post News
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewswire
Outlook Therapeutics Inc (OTLK) receives a Neutral rating from Chardan Capital Markets - Knox Daily
Major Clinical Trial Success: Revolutionary Eye Treatment Shows Promise in NORSE EIGHT Study - StockTitan
Analysis of Outlook Therapeutics (OTLK) - substack.com
Financial Analysis: Outlook Therapeutics Inc (OTLK)’s Ratios Unveil Key Insights - The Dwinnex
OTLK’s Market Whiplash: -2.12% YTD Decline, -2.12% Plunge in 30 Days - The InvestChronicle
Outlook Therapeutics appoints Faisal Sukhtian as chairman - The Pharma Letter
Outlook Therapeutics Secures Funding and Board Restructures - MSN
Outlook Therapeutics names new chairman amid product launch - MSN
Outlook Therapeutics names new chairman amid product launch By Investing.com - Investing.com Canada
Outlook Therapeutics Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - citybiz
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors - GlobeNewswire
Outlook's Strategic Leadership Shift: New Chairman Takes Helm as EU-Approved Eye Drug Nears Launch - StockTitan
Outlook Therapeutics announces CEO resignation - MSN
USdollar Index(DXY) Is Pointing Lower After A Pullback; Intraday Elliott Wave Analysis - The Globe and Mail
Outlook Therapeutics reports preliminary results from Norse Eight trials - MSN
Barclays PLC Buys 18,249 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Outlook Therapeutics® Announces Presentation of Efficacy - GlobeNewswire
Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD - GlobeNewswire
Outlook Therapeutics Announces Presentation of Efficacy and Safety Results from Norse Eight Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD - Marketscreener.com
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar - GlobeNewswire
Outlook Therapeutics CEO to Present at Webull Healthcare Webinar Following EU & UK Approval Success - StockTitan
Outlook plunges as lead asset fails in wet AMD study - MSN
Outlook Therapeutics’ (OTLK) “Buy” Rating Reiterated at HC Wainwright - Defense World
Outlook Therapeutics' (OTLK) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Outlook Therapeutics (NASDAQ:OTLK) Receives Buy Rating from HC Wainwright - MarketBeat
Short Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Drops By 17.7% - MarketBeat
Outlook Therapeutics Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - Marketscreener.com
HC Wainwright Reaffirms "Buy" Rating for Outlook Therapeutics (NASDAQ:OTLK) - MarketBeat
Outlook Therapeutics, Inc. Completes the Analysis of the Complete 12-Week Safety and Efficacy Results for NORSE EIGHT - Marketscreener.com
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Yahoo Finance
Outlook falls 10% on ONS-5010 update, warrant inducements - MSN
Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial - Marketscreener.com
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - GlobeNewswire
Outlook Therapeutics' ONS-5010 Matches Ranibizumab in 12-Week AMD Trial Results - StockTitan
Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $32.73 - Defense World
Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Outlook Therapeutics Reports 2024 Financial Results - MSN
Barclays PLC Increases Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World
My Top 5 Artificial Intelligence Stocks to Buy for 2025 - The Globe and Mail
OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Outlook Therapeutics® Participates in Virtual Investor "What This Means” Segment - The Manila Times
Outlook's LYTENAVA Makes History: First Approved Ophthalmic Bevacizumab for Wet AMD in UK - StockTitan
Outlook Therapeutics Inc Stock (OTLK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Outlook Therapeutics Inc Stock (OTLK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Haddadin Yezan Munther | Director |
Mar 28 '24 |
Buy |
11.82 |
1,882 |
22,242 |
5,049 |
| Evanson Jeff | CHIEF COMMERCIAL OFFICER |
Mar 07 '24 |
Buy |
0.42 |
62,484 |
26,243 |
808,459 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):